A Madison startup called Voximetry has gotten FDA clearance for a tool that can estimate the amount of radiation absorbed by patients following treatment or diagnosis with radiopharmaceuticals.
In a statement, Voximetry CEO Sue Wallance said the agency’s approval represents “an important first step on the path to accurate personalized treatments that may include increased tumor response or improved protection for critical organs.”
Read full story at https://www.wisbusiness.com/2023/voximetry-gets-fda-approval-for-assessment-tool/
Nots: Voximetry is a Discovery to Product (D2P) innovator.